公开(公告)号：US11248264B2

公开(公告)日：2022-02-15

申请号：US16920286

申请日：2020-07-02

Applicant: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH ,  BioNTech SE

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Mustafa Diken ,  Jan Diekmann ,  Michael Koslowski ,  Cedrik Britten ,  John Christopher Castle ,  Martin Löwer ,  Bernhard Renard ,  Tana Omokoko ,  Johannes Hendrikus De Graaf

IPC: A61K39/00 ,  C12Q1/6869 ,  G16B20/00 ,  G16B40/00 ,  C12Q1/6886 ,  G16B20/20

Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

公开(公告)号：US20210283177A1

公开(公告)日：2021-09-16

申请号：US16478615

申请日：2018-09-17

Applicant: Biontech SE ,  University of Verona

Inventor： Ugur Sahin ,  Vincenzo Bronte ,  Stefano Ugel ,  Alessandra Fiore

IPC: A61K35/15 ,  C07K14/47 ,  C12N5/0786 ,  C12N5/0775 ,  A61P37/06

Abstract: The present invention relates to cells which are engineered so as to increase the cellular level of cellular FLICE [Fas-associated death domain (FADD)-like IL-1β-converting enzyme]—inhibitory protein (CFLAR). The engineered cells have the ability to induce tolerance. Enhanced tolerogenicity is useful for prolonging survival of a foreign transplant and for treatment of autoimmune diseases.

公开(公告)号：US20240390524A1

公开(公告)日：2024-11-28

申请号：US18628304

申请日：2024-04-05

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Gábor Boros ,  Azita Josefine Mahiny ,  Jonas Reinholz ,  Katalin Karikó

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.

公开(公告)号：US20240254249A1

公开(公告)日：2024-08-01

申请号：US18481578

申请日：2023-10-05

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20240158501A1

公开(公告)日：2024-05-16

申请号：US18468103

申请日：2023-09-15

Applicant: BioNTech SE ,  Astellas Pharma Inc.

Inventor： Ugur Sahin ,  Christiane Stadler ,  Leyla Fischer ,  Arne Jendretzki ,  Özlem Türeci ,  Fabrice Le Gall ,  Maria Kreuzberg

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/86

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/28 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73

Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

公开(公告)号：US11951185B2

公开(公告)日：2024-04-09

申请号：US17565921

申请日：2021-12-30

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Gábor Boros ,  Azita Josefine Mahiny ,  Jonas Reinholz ,  Katalin Karikó

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00

CPC classification number: A61K48/0066 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/215 ,  A61K48/0033 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  C12N2770/18022 ,  C12N2770/18034 ,  C12N2770/18071 ,  C12N2770/20034 ,  C12N2840/00

Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.

公开(公告)号：US11932693B2

公开(公告)日：2024-03-19

申请号：US18315686

申请日：2023-05-11

Applicant: BioNTech SE ,  Genmab A/S

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Friederike Gieseke ,  Karsten Beckmann ,  Claudia Paulmann ,  Alexander Muik ,  Ivan Kuzmanov ,  Esther Cornelia Wilhelmina Breij ,  Patricia Garrido Castro ,  Jordan Blum ,  Lars Guelen ,  Joost Neijssen ,  Bart-Jan De Kreuk ,  Richard Hibbert ,  Janine Schuurman ,  Aran Frank Labrijn

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

公开(公告)号：US20240084288A1

公开(公告)日：2024-03-14

申请号：US18515879

申请日：2023-11-21

Applicant: BioNTech SE

Inventor： Katalin Kariko ,  Ugur Sahin

IPC: C12N15/10 ,  C07K14/505 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

CPC classification number: C12N15/102 ,  C07K14/505 ,  C12N15/10 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.

公开(公告)号：US11925694B2

公开(公告)日：2024-03-12

申请号：US17698829

申请日：2022-03-18

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61P31/14 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61K48/00 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00

CPC classification number: A61K48/0066 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/215 ,  A61K48/0033 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  C12N2770/18022 ,  C12N2770/18034 ,  C12N2770/18071 ,  C12N2770/20034 ,  C12N2840/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20240041999A1

公开(公告)日：2024-02-08

申请号：US18258343

申请日：2021-12-20

Applicant: BioNTech SE

Inventor： Mathias Vormehr ,  Lena Mareen Kranz ,  Ugur Sahin ,  David Eisel

IPC: A61K39/00 ,  A61P37/02

CPC classification number: A61K39/001111 ,  A61P37/02 ,  A61K2039/53 ,  A61K2039/55533 ,  A61K2039/55555 ,  A61K2039/545

Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.